Endocarditis Clinical Trial
Official title:
Suppressive Antibiotic Therapy for Prosthetic Valve or Implantable Device Related Infectious Endocarditis
Endocarditis are deadly infections, which nowadays occurs mainly among older patients with multiple comorbidities. The incidence is notably high among patients with valvular prosthetic or implantable devices. Management of such situation usually requires intravenous antibiotic therapy along with removal of the infected prosthetic or device. However, such invasive procedures and revision surgeries may be judged unreasonable among these patients, who are then exposed to a high risk of infectious relapse when curative antibiotics are discontinued. In these situation, a long-course antibiotic therapy may be used in order to maintain lasting infection control, to limit the risks of relapse of infection due to the infected device retention, and ultimately to prolong survival. This strategy is already suggested in case of infected prosthesis joint retention (IDSA 2013), and has been proposed for implantable device retention by the American Heart Rhythm Society in 2017, but data regarding its modalities and outcomes are scare. The objectives of this study are to describe the survival of patient under long-term antibiotic therapy for endocarditis, at 6-months and 1 year after initiation. Secondary outcomes includes modalities of the suppressive treatment prescribed, its security (secondary effects, tolerance) and to precise causes of death.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05547607 -
Clinical and Diagnostic Features of Endocarditis
|
||
| Completed |
NCT00750373 -
Early Surgery Versus Conventional Treatment in Infective Endocarditis
|
Phase 4 | |
| Recruiting |
NCT03690076 -
Human Cardiac Mitochondria in Acute Endocarditis and Obesity
|
||
| Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
| Terminated |
NCT00995384 -
Cardiac Computed Tomography (CT) Scan Compared to Transesophageal Echocardiogram (TEE) in Endocarditis
|
N/A | |
| Completed |
NCT04309591 -
Cytosorb Therapy in Cardiac Surgery
|
||
| Recruiting |
NCT05142891 -
Renal Tolerance of Amoxicillin and Cloxacillin Combination
|
||
| Recruiting |
NCT05703022 -
Early Exercise Training in Patients Following Heart Valve Surgery for Infective Endocarditis.
|
N/A | |
| Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
| Completed |
NCT03377465 -
Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis
|
N/A | |
| Recruiting |
NCT03892174 -
Cytokine REmoval in CRitically Ill pAtients Requiring Surgical Therapy for Infective Endocarditis (RECReATE)
|
N/A | |
| Completed |
NCT03695861 -
Contribution of 18F-FDG PET-CT in the Diagnosis and the Detection of Peripheral Emboli of Infectious Endocarditis on Native Valves
|
N/A | |
| Recruiting |
NCT02759978 -
Individualized Diagnosis of Endocarditis and Its Therapy With a Focus on Infected Prosthetic materiAL
|
||
| Completed |
NCT00709358 -
Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections
|
Phase 4 | |
| Terminated |
NCT03148756 -
Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis
|
Phase 2 | |
| Enrolling by invitation |
NCT05156437 -
Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)
|
Phase 4 | |
| Completed |
NCT02251262 -
Diagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection
|
N/A | |
| Recruiting |
NCT03112356 -
The Value of 99mTc-Leukoscan® Scintigraphy in the Diagnosis of Infectious Endocarditis on Surgical Materials
|
Phase 4 | |
| Completed |
NCT01375257 -
Partial Oral Treatment of Endocarditis
|
Phase 4 | |
| Terminated |
NCT00590889 -
Artificial Valve Endocarditis Reduction Trial
|
N/A |